Elsevier

Clinical Therapeutics

Volume 30, Issue 2, February 2008, Pages 393-404
Clinical Therapeutics

Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease

https://doi.org/10.1016/j.clinthera.2008.02.016Get rights and content

Abstract

Background: Crohn's disease (CD) is a chronic inflammatory bowel disease usually diagnosed in early adult life and characterized by unpredictable flares and debilitating symptoms such as diarrhea, abdominal pain, and fever, which can interfere with a patient's ability to work and perform daily activities.

Objective: The aim of this study was to assess the validity, reliability, and responsiveness of the Work Productivity and Activity Impairment questionnaire in CD (WPAI:CD).

Methods: The WPAI:CD was tested in CD patients enrolled in a 26-week randomized clinical trial of cer-tolizumab pegol versus placebo. Discriminative validity of WPAI:CD absenteeism, presenteeism(reduced on-the-job effectiveness), overall work productivity loss (absenteeism + presenteeism), and activity impairment scores was assessed relative to 5 measures of disease severity and health status: CD Activity Index (CDAI), Short Form-36 physical component summary (PCS) and mental health component summary (MCS) scores, Inflammatory Bowel Disease Questionnaire (IBDQ), and the 5-dimensional EuroQoL health-related quality-of-life visual analog scale (EQ-VAS). Responsiveness was assessed by comparing changes in WPAI:CD scores from baseline to week 26 for patients in remission (CDAI <150 points) versus no remission. Standardized Response Means (SRMs) were calculated to evaluate the magnitude of the changes.

Results: A total of 662 patients (mean [range] age, 37.4 [18–77] years; male, 288 [43.5%]; white, 629 [95.0%]) were enrolled in the study. Patients with CD of the worst severity (CDAI > median) showed significantly higher impairment in work (+10.5%) and activities (+10.4%) versus patients with "best health" (no problems) (both, P ≤ 0.001). Patients with "worst" IBDQ, PCS, MCS, and EQ-VAS scores also showed significantly higher impairments in work (IBDQ, VAS -24.2%; PCS, -24.1%; MCS, -15.9%; EQ-VAS, -16.5%) and activities (IBDQ, -23.3%; PCS, -21.8%; MCS, -16.5%; EQ-VAS, -17.2%) versus "best" scores (all, P < 0.05). There were significant differences between WPAI:CD impairment scores for patients in remission versus patients failing to achieve remission (P < 0.05). SRMs were small (ie, <0.5) in the nonre-mission group, and moderate to large (ie, >0.5) for patients in remission.

Conclusions: The discriminative validity, reliability, and responsiveness of the WPAI:CD were demonstrated. The WPAI:CD may be useful for evaluating drug impact on CD.

References (44)

  • EJ Irvine et al.

    Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease

    Gastroenterology

    (1994)
  • JL Severens et al.

    Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands

    Soc Sci Med

    (2000)
  • MC Gawlicki et al.

    Linguistic validation of the US Spanish Work Productivity and Activity Impairment questionnaire, general health version

    Value Health

    (2006)
  • K Sanderson et al.

    Which presenteeism measures are more sensitive to depression and anxiety?

    J Affect Disord

    (2007)
  • T Bernklev et al.

    Health-related quality of life in patients with inflammatory bowel disease measured with the Short Form-36: Psychometric assessments and a comparison with general population norms

    Inflamm Bowel Dis

    (2005)
  • F Casellas et al.

    Impairment of health-related quality of life in patients with inflammatory bowel disease: A Spanish multicenter study

    Inflamm Bowel Dis

    (2005)
  • EJ Irvine

    Development and subsequent refinement of the Inflammatory Bowel Disease Questionnaire: A quality-of-life instrument for adult patients with inflammatory bowel disease

    J Pediatr Gastroenterol Nutr

    (1999)
  • GP Rubin et al.

    Inflammatory bowel disease: Epidemiology and management in an English general practice population

    Aliment Pharmacol Ther

    (2000)
  • CG Loftus et al.

    Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000

    Inflamm Bowel Dis

    (2007)
  • TR Yapp et al.

    Crohn's disease incidence in Cardiff from 1930: An update for 1991-1995

    Eur J Gastroenterol Hepatol

    (2000)
  • A Ekbom et al.

    Cost to society of Crohn's disease

    Res Clin Forums

    (1998)
  • M Rösch et al.

    Cost measurement based on a cost diary in patients with inflammatory bowel disease [in German]

    Z Gastroenterol

    (2002)
  • Cited by (135)

    • Impact of allergic contact dermatitis on the work productivity: Workers from southern Tunisia

      2023, Archives des Maladies Professionnelles et de l'Environnement
    View all citing articles on Scopus
    View full text